Abstract:Objective: The RNA-binding protein RBM10 can regulate apoptosis during the proliferation and migration of pancreatic cancer, endometrial cancer, and osteosarcoma cells; however, the molecular mechanism underlying lung adenocarcinoma is rarely reported. Recent studies have detected multiple truncated and missense mutations in RBM10 in lung adenocarcinoma, but the role of RBM10 in lung adenocarcinoma is unclear. This study mainly explored the immune regulation mechanism of RBM10 in the development of lung adenocarcinoma and its influence on sensitivity to targeted therapy drugs. Methods: The transcriptome data of CGAP were used to analyze the RNA-seq data of lung adenocarcinoma patients from different subgroups by using the CIBERSORT algorithm to infer the relative proportion of various immune infiltrating cells, and Spearman correlation analysis was performed to determine the gene expression and immune cell content. In addition, this study utilized drug trial data from the GDSC database. The IC50 estimates for each specific targeted therapy were obtained by using a regression method, and the regression and prediction accuracy were tested via ten cross-validations with the GDSC training set. An immunohistochemical test was performed on the samples of 20 patients with lung adenocarcinoma in the subcomponent analysis of immune cells, and the protein expression of RBM10 in lung adenocarcinoma tissues was verified by cellular immunofluorescence assays. Nucleic acids were extracted at low temperatures, and qRT-PCR was used to verify the expression levels of the mRNA of RBM10 in lung adenocarcinoma tissues and normal tissues (p < 0.05). Results: After screening and inclusion using a machine language, the results showed that RBM10 was significantly highly expressed in the lung adenocarcinoma tissues. The related signaling pathways were mainly concentrated in ncRNA processing, rRNA metabolic processes, ribosome biogenesis, and the regulation of translation. The qRT-PCR for 20 lung adenocarcinoma tissues showed that the expression of RBM10 in these tissues was significantly different from that in normal tissues (p = 0.0255). Immunohistochemistry analysis and cell immunofluorescence staining also confirmed that RBM10 was involved in the immune regulation of lung adenocarcinoma tissues, and the number of immune cell aggregations was significantly higher than that of the control group. RBM10 regulates B cell memory-CIBERSORT (p = 0.042) and B cell memory-CIBERSOTRT-abs (p = 0.027), cancer-associated fibroblast-EPIC (p = 0.001), cancer-associated fibroblast- MCPCounter (p = 0.0037), etc. The risk score was significantly associated with the sensitivity of patients to lapatinib (p = 0.049), nilotinib (p = 0.015), pazopanib (p = 0.001), and sorafenib (p = 0.048). Conclusions: RBM10 can inhibit the proliferation and invasion of lung adenocarcinoma cells through negative regulation and promote the apoptosis of lung adenocarcinoma cells through immunomodulatory mechanisms. The expression level of RBM10 affects the efficacy of targeted drug therapy and the survival prognosis of lung adenocarcinoma patients, which has a certain guiding significance for the clinical treatment of these patients.

The Human RNA Binding Motif Protein RBM10 Modulates Apoptosis by Influencing Tumour Necrosis Factor Expression

RBM10 Modulates Apoptosis and Influences TNF-α Gene Expression.

Upregulation of TNF-alpha in Lung Cancer Cells Overexpressing the Apoptosis Modulator and Putative Tumour Suppressor RBM5

Data from Genetic Ablation of <i>rbm38</i> Promotes Lymphomagenesis in the Context of Mutant P53 by Downregulating PTEN

RBM10 Regulates Tumor Apoptosis, Proliferation, and Metastasis

Abstract 2988: Loss of Rbm38 Cooperates with Mutant P53 to Promote Lymphomagenesis Through Downregulation of Pten

Crystal structure and functional characterization of the human RBM25 PWI domain and its flanking basic region.

RBM10 regulates the tumorigenic potential of human cancer cells by modulating PPM1B and YBX1 activities

The apoptosis modulator and tumour suppressor protein RBM5 is a phosphoprotein.

RBM10 Inhibits Cell Proliferation of Lung Adenocarcinoma Via RAP1/AKT/CREB Signalling Pathway.

RBM5 as a Putative Tumor Suppressor Gene for Lung Cancer:

RNA Binding Motif Protein 10 Suppresses Lung Cancer Progression by Controlling Alternative Splicing of Eukaryotic Translation Initiation Factor 4H

Global RNA Interaction and Transcriptome Profiles Demonstrate the Potential Anti-Oncogenic Targets and Pathways of RBM6 in HeLa Cells

Up-regulation of the Proapoptotic Caspase 2 Splicing Isoform by a Candidate Tumor Suppressor, RBM5.

The tumor suppressor gene RBM5 inhibits lung adenocarcinoma cell growth and induces apoptosis

Multiple Omics Analysis of the Role of RBM10 Gene Instability in Immune Regulation and Drug Sensitivity in Patients with Lung Adenocarcinoma (LUAD)

RBM15 Promotes Hepatocellular Carcinoma Progression by Regulating N6-methyladenosine Modification of YES1 Mrna in an IGF2BP1-dependent Manner.

RBM10 recruits METTL3 to induce N6-methyladenosine-MALAT1-dependent modification, inhibiting the invasion and migration of NSCLC

Autoregulation of RBM10 and cross-regulation of RBM10/RBM5 via alternative splicing-coupled nonsense-mediated decay.

Functional Analysis Reveals That RBM10 Mutations Contribute to Lung Adenocarcinoma Pathogenesis by Deregulating Splicing.